A Study of LY2951742 in Healthy Japanese and Caucasian Participants

NCT02104765 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine Disorders

Interventions

DRUG: LY2951742
DRUG: Placebo

Sponsor

Eli Lilly and Company